Piotr Trzonkowski
Chief Executive Officer PolTREG/Immuthera
Seminars
Wednesday 25th February 2026
T regulatory cells in the treatment of autoimmune diseases – therapy built on experience with patients
12:00 pm
- Clinical trials with ex vivo manufactured polyclonal T regulatory cells (Tregs) led to first authorisations of this cellular therapy in GvHD and type 1 diabetes
- Thorough analysis of the immune system of the patients treated in trials led to novel generations of cellular therapies around Tregs now heading towards clinical phase
- Novel generations of Tregs can be prepared as autologous and allogeneic medicinal products, which facilitates scaling up of the manufacturing and delivery to all patients in the need of Tregs therapy
